NEW YORK (GenomeWeb) – Exact Sciences reported before the opening of the market on Wednesday that third quarter revenues increased 123 percent, due to a 100 percent uptick in the number of Cologuard colon cancer tests it completed during the quarter.

For the quarter ended Sept. 30, the molecular diagnostics company reported revenues of $28.1 million, up from $12.6 million in the year-ago quarter, and beating the average Wall Street analyst estimate for revenues of $25.3 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Hundreds of scientists have signed a letter criticizing the open-access Plan S, ScienceInsider reports.

NPR speaks with Rep. Eddie Bernice Johnson (D-Texas) about the US House of Representatives science committee.

A start-up company aiming to match cancer patients to treatments closes after about six weeks, Stat News reports.

In PLOS this week: somatic mutation associations unearthed in thousands of cancer exomes, pathogen detection assay, and more.